Ocular Manifestation and Related Risk Factors of Covid-19 Associated Mucormycosis: a Multicenter Study in Iran

• Conditions: COVID-19; Mucormycosis

• Registration Number: NCT05097664
• Lead Sponsor: Isfahan University of Medical Sciences

Brief Summary

Coronavirus disease 2019 (COVID-19) infection caused by the novel severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) may manifest as a variety of disease patterns, ranging from mild to life-threatening pneumonia.

Mucormycosis has been suspected to cause significant morbidity in infected people since the outbreak of the COVID-19 pandemic. Individuals who require hospitalization and intensive care are more vulnerable, as they have reached an advanced stage of their disease. Investigators will discuss the major risk factors, ocular presentation, and outcome of mucormycosis in individuals infected with SARS-CoV-2 in this study. From August 2021 to January 2022, a cross-sectional descriptive multicenter investigation would be conducted on patients with biopsy-confirmed mucormycosis and RTPCR confirmed COVID19. Demographic data, the time interval between COVID19 and mucormycosis, underlying systemic disorders, clinical characteristics, disease course, and outcomes would be analyzed.

Detailed Description

Investigators will achieved the following data from the participants:

1. Demographic

2. Past medical/habitual history

3. COVID-19 status and related risk factors

4. Mucormycosis status and related risk factors

5. Ocular examination and imaging

6. Follow-up

Study Timeline

• Study Start: 2021-08-23
• Status Verified: 2021-10
• Study First Submitted: 2021-10-23
• Study First Submitted QC: 2021-10-26
• Last Update Submitted: 2021-10-26
• Study First Posted: 2021-10-28
• Last Update Posted: 2021-10-28
• Primary Completion: 2021-11-21
• Study Completion: 2022-01-20

Recruitment & Eligibility

• Status: UNKNOWN
• Sex: All
• Target Recruitment: 250

Inclusion Criteria

• Diagnosed case of Mucormycosis in COVID-19 pandemic

Exclusion Criteria

• People with acute or severely ill conditions that prevent them from ophthalmic examination.
• Patient, or legal representative opposing the pursuit of the research

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Vision loss	3 months	Prevalence of Vision loss in COVID-19 patients with Mucormycosis co-infection

Secondary Outcome Measures

Name	Time	Method
Risk factors	3 months	Related risk factors for vision loss

Trial Locations

Locations (1)

Isfahan University of Medical Sciences; 🇮🇷 Isfahan, Iran, Islamic Republic of